Russell Investments Group Ltd. Increases Stock Position in Ultragenyx Pharmaceutical Inc. $RARE

Russell Investments Group Ltd. boosted its holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 599.2% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 840,451 shares of the biopharmaceutical company’s stock after buying an additional 720,256 shares during the period. Russell Investments Group Ltd.’s holdings in Ultragenyx Pharmaceutical were worth $25,281,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in RARE. Norges Bank purchased a new position in shares of Ultragenyx Pharmaceutical in the second quarter worth $35,765,000. Hsbc Holdings PLC lifted its holdings in shares of Ultragenyx Pharmaceutical by 88.6% during the second quarter. Hsbc Holdings PLC now owns 97,197 shares of the biopharmaceutical company’s stock valued at $3,554,000 after purchasing an additional 45,665 shares in the last quarter. Skandinaviska Enskilda Banken AB publ boosted its position in shares of Ultragenyx Pharmaceutical by 108.1% during the second quarter. Skandinaviska Enskilda Banken AB publ now owns 67,720 shares of the biopharmaceutical company’s stock valued at $2,462,000 after buying an additional 35,185 shares during the last quarter. Frazier Life Sciences Management L.P. boosted its position in shares of Ultragenyx Pharmaceutical by 49.3% during the second quarter. Frazier Life Sciences Management L.P. now owns 983,715 shares of the biopharmaceutical company’s stock valued at $35,768,000 after buying an additional 325,000 shares during the last quarter. Finally, Schroder Investment Management Group increased its holdings in Ultragenyx Pharmaceutical by 27.2% in the 2nd quarter. Schroder Investment Management Group now owns 336,173 shares of the biopharmaceutical company’s stock worth $12,223,000 after buying an additional 71,888 shares in the last quarter. 97.67% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about Ultragenyx Pharmaceutical

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: Late‑stage win — Ultragenyx reported positive 36‑week Phase 3 results for DTX301 (AAV8 gene therapy) in OTC deficiency showing sustained ammonia reductions and improved metabolic control, a clear clinical proof‑point that could support a regulatory filing and a large addressable market for a first‑in‑class therapy. Article Title
• Neutral Sentiment: Analyst action — JPMorgan materially lowered its price target from $120 to $74 but kept an Overweight rating, signalling confidence in the longer‑term thesis while trimming upside assumptions; this tempers but does not reverse buy‑side optimism. Article Title
• Negative Sentiment: Multiple securities‑class action notices — Several law firms (Rosen, Pomerantz, Schall, DJS, Levi & Korsinsky, others) have filed or solicited lead‑plaintiff applications alleging securities law violations for purchases between Aug 3, 2023 and Dec 26, 2025; April 6, 2026 is the commonly cited lead‑plaintiff deadline. The wave of litigation increases headline risk, potential legal costs, and near‑term selling pressure. Article Title

Insider Buying and Selling at Ultragenyx Pharmaceutical

In other news, CFO Howard Horn sold 1,635 shares of Ultragenyx Pharmaceutical stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $22.40, for a total transaction of $36,624.00. Following the transaction, the chief financial officer owned 85,034 shares in the company, valued at $1,904,761.60. This trade represents a 1.89% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Karah Herdman Parschauer sold 8,135 shares of the business’s stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $22.80, for a total transaction of $185,478.00. Following the sale, the executive vice president directly owned 76,346 shares of the company’s stock, valued at approximately $1,740,688.80. The trade was a 9.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 104,958 shares of company stock valued at $2,394,858 in the last quarter. Insiders own 5.50% of the company’s stock.

Ultragenyx Pharmaceutical Stock Performance

Shares of NASDAQ:RARE opened at $21.71 on Friday. The stock’s 50-day simple moving average is $23.06 and its two-hundred day simple moving average is $28.88. The stock has a market capitalization of $2.10 billion, a price-to-earnings ratio of -3.72 and a beta of 0.16. Ultragenyx Pharmaceutical Inc. has a 52-week low of $18.41 and a 52-week high of $42.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings results on Thursday, February 12th. The biopharmaceutical company reported ($1.29) EPS for the quarter, missing the consensus estimate of ($1.20) by ($0.09). Ultragenyx Pharmaceutical had a negative net margin of 85.54% and a negative return on equity of 1,024.42%. The business had revenue of $207.28 million for the quarter, compared to analysts’ expectations of $199.60 million. During the same period in the previous year, the company earned ($1.39) EPS. Ultragenyx Pharmaceutical’s revenue for the quarter was up 25.5% compared to the same quarter last year. As a group, equities analysts forecast that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have weighed in on RARE shares. Robert W. Baird decreased their target price on Ultragenyx Pharmaceutical from $72.00 to $47.00 and set an “outperform” rating for the company in a research report on Tuesday, December 30th. Wells Fargo & Company reduced their price target on shares of Ultragenyx Pharmaceutical from $65.00 to $45.00 and set an “overweight” rating for the company in a research note on Tuesday, December 30th. Wedbush reissued a “neutral” rating and set a $25.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Tuesday, February 17th. HC Wainwright lowered their price objective on shares of Ultragenyx Pharmaceutical from $60.00 to $50.00 and set a “buy” rating on the stock in a research report on Tuesday, February 17th. Finally, Barclays dropped their target price on shares of Ultragenyx Pharmaceutical from $81.00 to $50.00 and set an “overweight” rating on the stock in a report on Monday, November 24th. Sixteen analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $65.76.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.